Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02677805
Other study ID # CPH-302-201030
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 30, 2016
Est. completion date November 3, 2017

Study information

Verified date May 2022
Source Croma-Pharma GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to assess the efficacy and safety of BoNT/a-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.


Description:

This multicenter Phase 3 study is comprised of two parts. The first part of the study is a randomized, double blind, placebo-controlled, phase which aims to demonstrate efficacy and safety of BoNT/A-DP compared with placebo. The second part is an open label extension phase to evaluate efficacy after repeat treatments and long term safety. Subjects can receive a maximum of four treatment cycles over the duration of the study, a single treatment in the first cycle compared with placebo, and up to three subsequent treatments in the open label extension study.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date November 3, 2017
Est. primary completion date September 15, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Aged = 18 years or older at time of screening - Has moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on FWS) as determined by in-clinic assessments by both the investigator and the subject(where: 0= 'none', 1= 'mild', 2= 'moderate', 3= 'severe'). Exclusion Criteria: - Any medical condition that may place the subject at increased risk due to exposure to botulinum toxin, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, profound atrophy or weakness in the target muscles, or any other condition (at the investigator's discretion) that might interfere with neuromuscular function or contraindicate botulinum toxin therapy. - Previous treatment with any serotype of botulinum toxin for any indication within the 12 months prior to screening, or any planned treatment with botulinum toxin of any serotype for any reason during the trial (other than the investigational treatment). - Active skin disease/infection or irritation at the treatment area. - Pregnant, breastfeeding or planning to become pregnant during the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum Toxin A
Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
Placebo
injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
Botulinum Toxin A - Open Label
Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Croma-Pharma GmbH

Outcome

Type Measure Description Time frame Safety issue
Primary Responder Rate at Week 4 Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of = 2 points in FWS score (at maximum frown) at week 4 visit relative to baseline, based on both the investigators'and the subjects'in-clinic assessments. week 4 relative to baseline
Secondary Percentage of responders at maximum frown at week 12 Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement =2 points in FWS score (at maximum frown) at the week 12 visit relative to baseline, based on both the investigator's and the subject's in-clinic assessment week 12
Secondary Percentage of responders at week 16 Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement =2 points in FWS score (at maximum frown) at the week 16 visit relative to baseline, based on both the investigator's and the subject's in-clinic assessment week 16
Secondary Subjects with a = 1 point reduction in FWS score The proportion of subjects with a = 1 point reduction in FWS score at rest at week 4 based separately on the investigators'and the subjects'in-clinic assessments week 4
Secondary Percentage of responders at week 20 or later Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement =2 points in FWS score (at maximum frown) at the week 20 visit (or later) relative to baseline, based on both the investigator's and the subject's in-clinic assessment week 20
Secondary Safety Evaluation Frequency, severity and causal relationship of AEs, SAes and AESIs trough study completion (60 weeks)
See also
  Status Clinical Trial Phase
Completed NCT02236312 - Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines Phase 2
Active, not recruiting NCT05565950 - AI-09 In Subjects With Glabellar Lines, GL-101 Phase 1/Phase 2
Completed NCT00430963 - IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines Phase 3
Recruiting NCT05083286 - Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines Early Phase 1
Completed NCT03687736 - Subject Satisfaction With AbobutulinumtoxinA Treatment Phase 4
Active, not recruiting NCT04281745 - Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® Phase 4
Active, not recruiting NCT05623410 - Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines Phase 3
Active, not recruiting NCT03440671 - The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines Phase 3
Completed NCT03736928 - Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines Phase 2
Completed NCT01808742 - Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device N/A
Completed NCT00777803 - NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines Phase 3
Completed NCT00430586 - Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines Phase 2
Completed NCT04281095 - A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines Phase 1/Phase 2
Completed NCT05146999 - Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines Phase 3
Completed NCT02428608 - Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 Phase 2
Completed NCT04143815 - Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines Phase 2
Not yet recruiting NCT05305768 - Xeomin Treatment of Glabellar Lines Using OLD Versus COLD Early Phase 1
Completed NCT05364580 - The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines Phase 3
Completed NCT05320393 - Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines Phase 2
Completed NCT01333397 - Safety and Efficacy Study of Dysport RU and Glabellar Lines Phase 2